Compare Harley-Davidson Inc (HOG) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harley-Davidson Inc vs Merck & Co., Inc. — how do they compare? Harley-Davidson Inc trades at $28.13 (market cap $2.93B), while Merck & Co., Inc. trades at $126.19 (market cap $307.25B). The key difference: Merck & Co., Inc. is far larger — about 104.9× Harley-Davidson Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| HOG | MRK | |
|---|---|---|
Market Cap | $2.93B | $307.25B |
Sector | Consumer Cyclical | Health |
52-Week High | $31.03 | $129.52 |
52-Week Low | $17.19 | $77.60 |
Enterprise Value | $3.32B | $350.66B |
Dividend Yield | 2.64% | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harley-Davidson (HOG) trades at $27.85, up 4.78% today, with a bullish technical signal from moving averages and a neutral RSI near 69. Recent earnings show mixed results, with Q1 2026 missing estimates, while revenue has declined from $5.8B in 2022 to $4.5B in 2025. The company is executing a turnaround strategy, including cost cuts and bringing Revolution Max engine production back to the U.S., amid positive retail sales growth in Q1 2026.
The outlook is cautious; while valuation ratios like P/E of 13.77 and P/B of 0.91 appear attractive, declining revenue and net income margins pose risks. Analyst consensus is mostly Hold (65.71%), with a price target of $23.40 below the current price, indicating skepticism about near-term growth despite operational initiatives.
Merck (MRK) trades at $124.30, down 2.51% over the past day, amid a generally bullish technical setup with moving averages signaling strength. The company reported solid earnings beats in recent quarters, including Q1 2026, with revenue reaching $65.01B in 2025 and net income of $18.25B. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives. Analyst sentiment remains strongly positive, with a consensus price target of $137.30 and 68% buy ratings.
The outlook for MRK is favorable, supported by robust profitability margins, strategic acquisitions, and strong institutional interest. Key risks include integration challenges from recent M&A, patent expirations, and regulatory pressures. The stock's current valuation at a P/E of 35.04 may limit near-term upside, but long-term growth drivers in pharmaceuticals provide a solid foundation for investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
